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Abstract: Traditionally available treatments, like cytotoxic chemotherapy and external-beam 
radiation therapy, are limited and essentially ineffective for metastatic medullary thyroid 
carcinoma (MTC). In the last decade, small-molecule tyrosine kinase inhibitors (TKI) have 
been introduced in the field of thyroid cancer, after having been shown effective in a wide 
variety of other tumors. This review focuses on vandetanib (ZD6474, ZactimaTM; AstraZeneca) 
and its role in the treatment of MTC. Vandetanib is an oral TKI that targets VEGF receptors 
2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. This 
drug has been tested in two important phase II studies which demonstrated that both the 100 
and 300 mg/day dosage of vandetanib have antitumor activity on advanced MTC. A phase III 
trial (ZETA trial) evaluating vandetanib in 331 patients with locally advanced or metastatic 
MTC showed a significant prolongation of PFS for patients receiving vandetanib compared 
with placebo. Toxicity surveillance in all studies reported high rates of adverse effects with 
diarrhea, rash, fatigue and nausea being the most commonly experienced by patients. Vandetanib 
is currently approved in the United States for unresectable locally advanced or metastatic MTC 
and has become a new standard of care in this rare and indolent pathology.
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Introduction
Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from 
parafollicular cells of the thyroid and which accounts for fewer than 10% of all 
diagnosed thyroid cancers. Characterized as a rare and indolent malignancy, it is 
nevertheless overrepresented among thyroid cancer-related deaths. Hereditary forms 
of this cancer account for 25% of cases, and include familial MTC (FMTC) and 
multiple endocrine neoplasia syndromes (MEN2A and MEN2B), but its more common 
presentation remains in its sporadic form (75% of cases).1 If diagnosed and treated at 
an early stage when the tumor is confined to the thyroid, MTC usually has a favorable 
prognosis, with a 10-year survival rate of 70%–80%.2 Conversely, locally advanced 
cervical disease and extra-cervical metastasis are incurable. Its distant metastatic form 
has the least favorable prognosis, a survival rate of 40% at 10 years, and it is the main 
cause of death in patients with MTC.2 Traditionally available treatments, like cytotoxic 
chemotherapy and external-beam radiation therapy, are limited and essentially 
ineffective for metastatic MTC. In the last decade, small-molecule tyrosine kinase 
inhibitors (TKI), which target multiple kinases, have been introduced in the field of 
thyroid cancer, after having been shown effective in a wide variety of other tumors. This 
review focuses on vandetanib (ZD6474, ZactimaTM; AstraZeneca, Mississauga, ON) 
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and on targeting rearranged during transfection (RET) 
receptor tyrosine kinase activation in MTC.
RET proto-oncogene
As is well known, MTC is associated with the RET proto-
oncogene on chromosome 10q11.2. The RET receptor protein 
is part of a large family of receptors, receptor tyrosine kinases 
(RTK), characterized for their role in cell growth, differentiation, 
survival, and programmed cell death.3 In response to binding of 
extracellular ligands, RTKs form homodimers or heterodimers. 
After dimerization, autophosphorylation followed by 
intracellular signal transduction occur through effectors that 
recognize and interact with the phosphorylated form of RTK4 
(Figure 1). This ligand–receptor interaction is very specific, 
while the downstream signaling pathways may be shared by 
different receptors.4
RET was one of the first RTKs to be implicated in 
  tumorigenesis. Germline mutations in the RET proto-
  oncogene are responsible for hereditary MTC while up to 
half of the sporadic forms of MTC harbor somatic RET muta-
tions.5,6 This provides a strong rationale for   targeting RET 
in selective cancer therapy. Moreover, RET gene mutations 
have a high correlation between genotype and   phenotype, 
with a clear link between the identified   mutation and tumor 
behavior, thus affecting aggressiveness of   treatment and   
follow-up.3
Vascular endothelial growth factor 
receptor pathway
The vascular endothelial growth factor receptor (VEGFR) 
pathway is also important in the pathogenesis of MTC.7 
There are three transmembrane receptors that mediate the 
angiogenic and lymphogenic effects of VEGF: VEGFR-1, 
VEGFR-2, and VEGFR-3. VEGFR-2 is thought to be the 
one implicated in tumor growth and metastasis, as it plays a 
role in endothelial cell proliferation, migration, and survival 
as well as induction of neovascularization (Figure 2). Tumor 
cells secrete VEGF proteins (VEGF-A, B, C, and D) that act 
as ligands for the VEGF receptors, which initiate a cascade of 
different pathways including PLC γ–PKC–Raf–MEK–MAPK 
and PI3K–Akt, towards promoting angiogenesis.8 There is 
a twofold overexpression of VEGF and VEGFR-2 in MTC 
when compared to normal thyroid tissue.7 Overexpression of 
VEGFR-2 in MTC correlates with metastasis.9
Other TK receptors implicated  
in MTC tumorigenesis
Epidermal growth factor receptor (EGFR) is a TK receptor 
that acts downstream through activation of several cascades, 
including MAPK and Pi3K pathways. Although EGFR 
mutations are rare, a study of 153 primary and metastatic 
MTC samples showed that EGFR expression was more 
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Figure 1 interaction of ligand with RET and cell-signaling pathways. 
Abbreviations: AKT, serine/threonine protein kinase; ECLD, extracellular ligand domain; FRS 2, fibroblast growth factor receptor substrate 2; GDNF, glial cell line-derived 
neurotrophic factor; GFRα, GDNF family receptor; IRS 1–2, insulin receptor substrate 1 and 2; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; 
RAS/ERK, extracellular signal-regulated kinase; PKC, protein kinase C; RET, rearranged during transcription; SHC, Src homology and collagen; TKD, tyrosine kinase domain; 
TMD, transmembrane domain.
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important in metastasis than in the  primary  tumor  site 
of MTC.9
The c-met (MET) proto-oncogene also plays a role in 
tumor cell proliferation. It codes for the TK receptor of 
the hepatocyte growth factor.8 Its overexpression has been 
reported in mutifocal MTC.10
Vandetanib as a targeted therapy
A few different pathways are activated in MTC cells. No 
selective RET inhibitor is currently available, but a few 
multikinase inhibitors have significant activity against 
RET. Small-molecule tyrosine kinase inhibitors (TKI) 
typically affect multiple signaling pathways. Vandetanib is 
a 4-anilinoquinazoline, available as an oral TKI that targets 
VEGF receptors 2 and 3, RET, and at higher concentrations, 
EGFR.11 It docks to the adenosine triphosphate (ATP)-
binding pocket of the RET kinase which confers an inhibiting 
effect.12 It was initially developed as a second-generation 
EGF receptor TKI, as its more potent inhibitory effects 
against VEGF receptor were demonstrated later on.3 In 
thyroid cancer cell lines, it was shown to be effective in 
inhibiting RET/PTC1 and RET/PTC3 mutations in some 
PTCs and M918T RET mutations in MEN2B and some 
sporadic MTCs. RET mutations in certain inherited forms 
of MTC, as in codon 804 and 806, seem to confer resistance 
to vandetanib.13,14
Preclinical studies
Vandetanib was shown to be effective in in vitro studies by 
inhibiting VEGF- and EGF-stimulated cell growth, with 
activities (50% inhibitory concentration, [IC50]) on tyrosine 
kinases of 1600 nM for VEGFR1, 40 nM for VEGFR2, 
108 nM for VEGFR3, and 500 nM for EGFR.15 It also 
inhibits RET proto-oncogenic kinase (IC50, 100 nM) and 
RET-dependent thyroid tumor cell proliferation in vitro.16
In MTC cells bearing a RETC634W-activating mutation, 
vandetanib (200 nM) has a significant antiproliferative effect 
as soon as 3 days after treatment introduction. After 6 days, 
vandetanib (250 nM) reduces calcitonin secretion (1.9-fold) 
and calcitonin mRNA expression (twofold). In athymic 
mice bearing MTC tumors, vandetanib (50 mg/kg/day) 
induced a 14.5-fold reduction of tumor volume after 45 days 
of treatment. Treated xenografts displayed a significant 
decrease in the number of tumor cells, mitotic index (Ki67), 
and tumor angiogenesis (CD34 staining).17 Another group 
showed that upon RET inhibition applied on RETC634W 
and RETM918T mutated cell lines, adoptive stimulation of 
EGFR partially rescues proliferation, MAPK signaling, 
and expression of cell-cycle-related genes.18 This may 
suggest that simultaneous inhibition of RET and EGFR by 
vandetanib might overcome the risk of MTC cells escaping 
from RET blockade through compensatory over-activation 
of EGFR.
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Figure 2 VEGFR pathways within the tumor cell. 
Abbreviations:  AKT,  serine/threonine  protein  kinase;  FAK,  focal  adhesion  kinase-1;  MAPK,  mitogen-activated  protein  kinase;  NOS,  nitric  oxide  synthase;   
PI3K, phosphoinositide 3-kinase; PLC, phospholipase; PKC, protein kinase; Shc, proteins containing Src homology-2 domains; RAS, rat sarcoma; VEGF, vascular endothelial 
growth factor; VEGFR, VEGF receptor.
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The administration of vandetanib at different doses (12.5, 
25, 50, or 100 mg/kg/day) produced a significant, dose-
dependent inhibition of tumor growth15 and a significant 
reduction in tumor microvessel density19–22 in a very wide 
range of human tumor xenograft models, including breast, 
lung, prostate, colon, kidney, ovary, and others. Vandetanib 
also seems to be effective against anaplastic thyroid 
carcinoma (ATC), as it significantly inhibits tumor growth 
of ATC cell lines in vivo by more than 65% when compared 
to control.
A dynamic contrast-enhanced magnetic resonance 
imaging (MRI) analysis disclosed a dose-dependent reduction 
in contrast agent uptake by tumors as soon as 24 hours after 
starting vandetanib treatment in human xenograft models of 
prostate23 and colon24 cancer. Furthermore, it seems promising 
that metabolic imaging with 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET) was recently shown to 
assess changes in tumoral glucose metabolism profile as 
early as 3 days after initiation of vandetanib in human MTC-
bearing mice. The authors hypothesize that FDG-PET may 
be useful for identifying patients who respond to vandetanib 
early on in the course of treatment.25
A comparison was performed on the effect of four TKI 
(vandetanib, axitinib, sunitinib, and XL184) on cell prolif-
eration, RET expression, and autophosphorylation, as well 
as ERK activation in cell lines expressing either a MEN2A 
(MTC-TT), a MEN2B (MZ-CRC-1) mutation, or a RET/
PTC (TPC-1) rearrangement. The authors found that there 
was indeed specificity for different RET mutations, with 
vandetanib being the most potent inhibitor in MEN2B, and 
XL184 the most effective in MEN2A and PTC in vitro. No 
TKI was superior for all cell lines tested, indicating that 
mutation-specific therapies could be beneficial in treating 
MTC and PTC.26
Phase I clinical studies
In  order  to  determine  its  safety,  tolerability,  and 
  pharmacokinetics, three phase I single-agent clinical stud-
ies involving vandetanib in patients with solid malignant 
tumors refractory to standard therapy were published. The 
first trial included 77 American and Australian patients 
with various tumors, with colorectal cancer being the most 
  common.27 All but one patient experienced at least one 
adverse event (AE), with diarrhea, hypertension, and rash 
being the most   common dose-limiting toxicities (DLT). Seven 
patients experienced asymptomatic corrected QT (QTc) 
prolongation. The incidence of most adverse events appeared 
to be dose-dependent. Pharmacokinetic analysis revealed that 
a t½ of ∼120 hours, and a minimum of 28 days continuous oral 
dosing with vandetanib was required to achieve steady-state 
plasma concentrations. These data confirmed that vandetanib 
was suitable for once-daily oral administration and among the 
various doses ranging from 50 to 600 mg/day, 300 mg/day 
was recommended for further phase II studies. In this study, 
no patient achieved a complete or partial tumor response as 
evaluated by Response Evaluation Criteria in Solid Tumors 
(RECIST) 1.0.28
The second phase I study involved 18 Japanese patients 
with solid tumors, nine of which were non-small-cell lung 
cancer (NSCLC).29 The most common drug-related AEs 
were rash, asymptomatic prolongation of QTc interval, 
diarrhea, and proteinuria. Mean arterial blood pressure 
increased in most patients after multiple doses of ZD6474. 
QTc prolongation necessitated dose interruption in seven 
out of 12 patients, six of whom were able to resume vande-
tanib treatment at a reduced dosage. QTc prolongation was 
reported at all dosages studied, with no clear evidence of 
dose-dependency. No grade 4 drug-related AE was observed. 
Seven patients experienced grade 3 drug-related AEs, most 
commonly hypertension. Pharmacokinetics findings of the 
first phase I study were confirmed, and again the dose of 
300 mg/day was deemed appropriate because of hypertension 
and elevated alanine aminotransferase (ALT) levels being 
reported as DLTs in the 400-mg group. Objective tumor 
response was observed in four out of nine patients with 
NSCLC at doses of either 200 or 300 mg.
A third study included 36 Chinese patients with solid 
tumors, most being lung cancers, and among them, three 
patients had MTC.30 The most common drug-related AEs 
were rash and diarrhea. No QTc prolongation was observed, 
and most importantly, patients were receiving no more than 
300 mg/day of vandetanib. Of note, only one patient showed 
a partial tumor response, and this patient had MTC.
Phase II clinical studies
The first available phase II study using vandetanib in 
patients with unresectable MTC was performed by a group 
of investigators based in the United States and France.31 
Thirty patients with locally advanced or metastatic MTC 
were assigned to vandetanib 300 mg/day in this open-label, 
single-arm trial conducted at seven centers. All patients 
had a germline RET mutation, most with MEN2A (33% 
of the cohort). Among other key inclusion criteria was the 
presence of at least one measurable lesion according to 
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RECIST guidelines.32 The primary end-point of the study was 
objective response rate, and additional assessments included 
duration of response, disease control, progression-free 
survival (PFS), safety and tolerability, and changes in serum 
levels of calcitonin and carcinoembryonic antigen (CEA).
At study entry, 29 patients had distant metastases, 
including sites at liver (80%), lymph nodes (70%), and lung 
(63%). Twenty percent of patients (ie, six of 30 patients) 
experienced a confirmed partial response (median duration 
of response at data cutoff, 10.2 months). An additional 53% 
of patients (ie, 16 of 30 patients) experienced stable disease 
at $24 weeks, which yielded a disease control rate of 73% 
(ie, 22 of 30 patients). In 24 patients, serum calcitonin levels 
showed a 50% or greater decrease from baseline that was 
maintained for at least 4 weeks; 16 patients showed a similar 
reduction in serum CEA levels. The most common adverse 
events were diarrhea (70%), rash (67%), fatigue (63%), and 
nausea (63%).
The second phase II trial, performed by a group of 
investigators from Australia and the United States, had 
the same eligibility criteria.33 Included in the study were 
19 patients with unresectable and measurable MTC, all 
with RET positive status. It was an open-label, single arm 
trial using a lower dose of vandetanib of 100 mg/day. The 
primary objective of this study was also to assess the objective 
response rate with vandetanib according to RECIST,32 and 
the secondary objectives were identical to the first phase II 
trial by Wells et al.31
Eighteen patients had metastatic disease in liver (84%), 
bones and lungs (42% for each), and most had MEN2A 
(47%). Confirmed objective partial responses were observed 
in three patients, yielding an objective response rate of 
16% (95% confidence interval [CI]: 3.4–39.6). Stable 
disease lasting 24 weeks or longer was reported in a further 
10 patients (53%); disease control rate was therefore 68% 
(95% CI: 43.4–87.4). Serum levels of calcitonin and CEA 
showed a sustained 50% or greater decrease from baseline in 
16% (three of 19) and 5% (one of 19) of patients, respectively. 
There was no apparent association between RET germline 
mutation and clinical outcome in this study. Adverse events 
were predominantly of grade 1 or 2 and consistent with other 
vandetanib studies, namely diarrhea (47%), fatigue (42%), 
and rash (26%). The authors concluded that taken together, 
the two phase II studies demonstrate that both the 100 and 
300 mg/day dosage of vandetanib have antitumor activity 
on advanced MTC. No direct comparison of the efficacy at 
each dose level has been conducted; therefore no conclusion 
could be made with regard to the relative efficacy of the 100 
and 300 mg/day doses in MTC.
Phase III clinical study
According to these encouraging results, a group of 
investigators from the United States, France, Italy, and the 
United Kingdom performed an international randomized, 
placebo-controlled, double-blind, phase III study (ZETA) 
to evaluate vandetanib in patients with locally advanced or 
metastatic MTC.34 Adult patients were eligible if they had 
measurable, unresectable locally advanced or metastatic, 
hereditary or sporadic MTC. Another key inclusion criterion 
was a serum calcitonin level over 500 pg/mL. It is noteworthy 
that progression of disease at study entry was not mandatory. 
Patients were randomly assigned in a 2:1 ratio to receive oral 
vandetanib at a starting dose of 300 mg/day or placebo until 
disease progression. Upon objective disease progression, 
patients discontinued the study drug, were unblinded, and 
could enter postprogression, open-label treatment with 
vandetanib. The primary objective was to determine whether 
vandetanib prolonged PFS, and secondary assessments 
included objective response rate, disease control rate at 
24 weeks, duration of response, overall survival, biochemical 
response (decrease in calcitonin and CEA serum levels), and 
time to worsening of pain.
Three hundred thirty-one patients recruited from 
23 countries were randomly assigned to either vandetanib 
(231) or placebo (100). The majority of patients presented 
with sporadic disease, and almost all had metastatic disease 
at study entry. The most common metastatic sites were 
liver, lymph nodes, and lungs. At data cut-off, the median 
duration of follow-up was 24 months, and 139 patients were 
continuing blinded treatment: 111 (48%) were randomly 
assigned to vandetanib and 28 (28%) to placebo. Significant 
prolongation of PFS was observed for patients receiving 
vandetanib compared with placebo (hazard ratio [HR], 
0.46; 95% CI: 0.31–0.69; P , 0.001). The median PFS was 
19.3 months in the placebo group and, although the median 
had not yet been reached for the vandetanib group, a statistical 
model indicated a predicted median PFS of 30.5 months. 
Vandetanib also showed significant benefits compared to 
placebo in the secondary efficacy end-points of objective 
response rate, disease control rate, and calcitonin and CEA 
biochemical response rates. As expected, overall survival 
data were immature at data cut-off. Interestingly, in patients 
with sporadic MTC, a subgroup analysis of PFS by M918T 
somatic mutation suggested that the patients who were 
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mutation-positive had a higher response rate to vandetanib 
compared with M918T mutation-negative patients. Adverse 
events such as diarrhea, rash, nausea, and hypertension 
occurred in more than 30% of patients receiving vandetanib. 
Twelve percent of patients on vandetanib discontinued 
treatment during the randomized phase because of an adverse 
event (versus 3% in patients receiving placebo). This rate of 
treatment discontinuation because of toxicity was considered 
low by the authors, despite a median duration of treatment of 
approximately 1 year and 9 months. Nineteen patients (8%) 
developed protocol-defined QTc prolongation, but there 
were no reports of torsade de pointes. Five patients on the 
vandetanib arm experienced adverse events leading to death 
during the randomized phase; these were single instances of 
aspiration pneumonia, respiratory arrest, respiratory failure, 
staphylococcal sepsis, and arrhythmia and acute cardiac 
failure in one patient.
Toxicity of vandetanib
As reported above in clinical studies, the most common 
toxicities of vandetanib in MTC are diarrhea, fatigue, rash, 
and nausea. As most patients will develop an adverse event 
on the recommended dose of 300 mg/day (see Table 1), 
the drug prescriber should be comfortable with treatment 
and follow-up of these toxicities.35 The majority of adverse 
events reported were manageable according to standard clini-
cal practice alone or in combination with vandetanib dose 
reductions, which allowed patients to continue receiving 
vandetanib treatment for extended periods of time.
Unusual adverse events have been reported. A case of 
reversible cerebral vasoconstriction syndrome has been 
documented in a patient with metastatic MTC, presenting 
as a severe acute headache and nausea 3 days after 
  starting vandetanib.36 The cerebral arteriography showed 
a characteristic string-bead pattern of alternating areas of 
arterial stenosis and dilation. After vandetanib was stopped, 
the patient rapidly recovered from his symptoms and an 
angiography performed 3 months later documented complete 
resolution of arterial constriction.
Another miscellaneous complication of therapy with 
vandetanib is the development of corneal verticillata, also 
known as vortex keratopathy, reported in a patient treated 
for anaplastic astrocytoma and consisting of subepithelial 
whorls that may lead to ocular surface irritation and corneal 
erosions.37 The authors state that these corneal changes may 
be related to the anti-EGFR action of vandetanib and are 
implicated in the pathogenic mechanisms of ocular surface 
diseases involving rapid epithelial turnover.
Finally, one of the authors (MB) assessed the endocrine 
effects of vandetanib in 39 patients with progressive medullary 
or differentiated thyroid cancer included in two randomized 
placebo-controlled trials using vandetanib 300 mg/day.38 
On vandetanib treatment, calcium and vitamin D mean 
replacement doses were increased; calcium level remained 
unchanged, but serum 25(OH) vitamin D level decreased, 
and serum PTH and 1,25(OH)2 vitamin D levels increased, 
suggesting a decreased intestinal absorption of vitamin D or 
lack of sun exposure as a result of photosensitization induced by 
vandetanib. Levothyroxine had to be increased by 50 µg/day to 
maintain serum thyroid-stimulating hormone within the normal 
range, probably by increased type 3 deiodinase activity as 
described with sorafenib.39 In male patients, total testosterone, 
bioavailable testosterone, and sex hormone-binding globulin 
levels were increased for unknown reasons. Serum inhibin-B 
decreased and stimulated follicle-stimulating hormone 
increased coherently, suggesting a Sertoli cells insufficiency. 
Cortisol level increased as well as adrenocorticotropic and 
cortisol-binding globulin levels, but free urinary cortisol levels 
remained in the normal range. None of these changes were 
observed in patients randomized to the placebo arm.
Table 1 Major adverse events reported in 20% or more patients on vandetanib 300 mg/day versus placebo in MTC
Wells et al31 Wells et al34
Vandetanib 300 mg/day 
n = 30 (%)
Vandetanib 300 mg/day 
n = 231 (%)
Placebo  
n = 100 (%)
Grade 1–2 Grade 3+ Grade 1–2 Grade 3+ Grade 1–2 Grade 3+
Diarrhea 60 10 45 11 4 2
Fatigue 57 7 18 6 22 1
Rash 63 3 41 4 10 1
Nausea 63 10 33 NR 16 NR
Hypertension 23 10 23 9 5 0
ECG QTc prolongation NR 20 6 8 0 1
Decreased appetite 40 3 17 4 12 0
Abbreviations: ECG, electrocardiographic; MTC, medullary thyroid carcinoma; NR, data not reported; QTc, corrected QT.
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Role of vandetanib in the treatment 
of MTC
Vandetanib was approved by the US Food and Drug 
Administration (FDA) in April 2011.40 It is still under 
review in Europe and Canada. This drug is approved for 
patients with advanced locoregional or metastatic MTC that 
is unresectable, progressive and/or symptomatic. Patients 
experiencing a rapid calcitonin doubling-time, but yet with 
microscopic disease, are not part of the approved indications 
of the drug since benefits in that specific population are not 
known. Vandetanib has now become the new standard of 
care for patients with unresectable or metastatic MTC in the 
United States. Its use is however strictly regulated due to its 
potential cardiac toxicity, as mentioned above. These potential 
cardiac effects are addressed by the FDA in a black box 
warning. Monitoring with serial EKGs and serum potassium, 
calcium and magnesium levels (at baseline, 2–4 weeks, and 
8–12 weeks after treatment initiation and then every 3 months) 
is recommended.41 As with other TKI, vandetanib’s high cost 
may limit its availability to all patients.
Conclusion
In summary, with its development as a targeted agent and 
the encouraging phase II and III trials results, vandetanib is 
recognized as an effective therapy in advanced MTC.   Further 
studies of this drug in combination or in sequence with other 
TKIs are awaited as supplementary uses of vandetanib may 
emerge.
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